Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of Thoracic Oncology
Volume16
Issue number9
Publication statusPublished - 1 Sept 2021

Cite this